Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment.
Bienvenu, J
Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. [electronic resource] - The hematology journal : the official journal of the European Haematology Association 2001 - 378-84 p. digital
Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial
1466-4860
10.1038/sj.thj.6200133 doi
Aged
Aged, 80 and over
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents--administration & dosage
B-Lymphocytes--drug effects
Blood Cell Count
Complement Activation--drug effects
Complement C3a--drug effects
Humans
Kinetics
L-Lactate Dehydrogenase--blood
Lymphoma, B-Cell--drug therapy
Lymphoma, Large B-Cell, Diffuse--drug therapy
Middle Aged
Rituximab
Tumor Necrosis Factor-alpha--drug effects
Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. [electronic resource] - The hematology journal : the official journal of the European Haematology Association 2001 - 378-84 p. digital
Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial
1466-4860
10.1038/sj.thj.6200133 doi
Aged
Aged, 80 and over
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents--administration & dosage
B-Lymphocytes--drug effects
Blood Cell Count
Complement Activation--drug effects
Complement C3a--drug effects
Humans
Kinetics
L-Lactate Dehydrogenase--blood
Lymphoma, B-Cell--drug therapy
Lymphoma, Large B-Cell, Diffuse--drug therapy
Middle Aged
Rituximab
Tumor Necrosis Factor-alpha--drug effects